Back

Direct cost analysis of genetic testing for CYP2C19*2 and *3 loss of function variants in percutaneous coronary intervention patients

27 August 2022 (13:15 - 13:40)
Organised by:
Congress Presentation Part of: Coronary artery disease - Pharmacotherapy 1 Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Samuel Huxley

Mayo Clinic Hospital-Rochester, Rochester (United States of America)

4 More presentations in this session

Presentation thumbnail
Sodium-glucose co-transporter-2 inhibitors after acute myocardial infarction in type 2 diabetes patients: a population-based investigation from South Korea
Doctor O. Kwon (Seoul, KR)
Abstract Slides
Presentation thumbnail
Activation of mitochondrial telomerase reverses relative lymphopenia post myocardial infarction: results from the randomised, double-blinded TACTIC phase IIa pilot trial
Professor I. Spyridopoulos (Newcastle-Upon-Tyne, GB)
Abstract Slides
Presentation thumbnail
Blood pressure and clinical outcomes in patients with diabetes and stable coronary artery disease in THEMIS
Doctor M. Pareek (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
Effect of rivaroxaban monotherapy vs. combination with anti-platelet therapy in patients with atrial fibrillation and stable coronary artery disease across different body mass index categories
Doctor M. Ishii (Kumamoto, JP)
Abstract Slides

Access the full session

Session thumbnail
Coronary artery disease - Pharmacotherapy 1

The Event

Event poster

ESC Congress 2022

27 August 2022 13:15 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources